8-K/A: BioLife Solutions Amends Q2 Results, Raises Full-Year Revenue Guidance

BioLife Solutions has revised its second-quarter financial results to reflect a reduction in stock compensation expense and has increased its full-year revenue guidance.

Summary

• BioLife Solutions has amended its previously released Q2 2024 financial results due to a $2.1 million reduction in stock-based compensation expense related to its discontinued Global Cooling operations.
• The company's Q2 total revenue was $28.3 million, a 3% decrease year-over-year but a 6% increase sequentially.
• Cell Processing revenue was $18.0 million, down 4% year-over-year but up 11% sequentially.
• The company reported a GAAP gross margin of 51% and a non-GAAP adjusted gross margin of 52% for the second quarter.
• GAAP net loss from continuing operations was $7.1 million, which includes a $4.1 million write-off of an equity investment.
• Non-GAAP adjusted EBITDA was $4.8 million, or 17% of revenue, for the second quarter.
• BioLife Solutions has raised its full-year 2024 total revenue guidance to $99.0 million to $101.0 million and Cell Processing revenue guidance to $70.0 million to $71.0 million.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the increased revenue guidance, improved gross margins, and adjusted EBITDA. However, the year-over-year revenue decline and net loss temper the overall positive outlook.

Positives

• The company has shown three consecutive quarters of sequential revenue growth.
• Gross margins have expanded, and adjusted EBITDA has increased.
• The company is benefiting from its high-margin, recurring, and consumable product offerings.
• BioLife Solutions is strategically aligned with favorable trends in the cell and gene therapy market.
• The company's biopreservation franchise supports more than 70% of U.S. commercial CGT trials.
• The company has successfully divested its GCI freezer division.
• The company has updated its revenue guidance upwards for 2024.

Negatives

• Total revenue for Q2 2024 decreased by 3% year-over-year.
• Cell Processing revenue decreased by 4% year-over-year.
• The company experienced a GAAP net loss from continuing operations of $7.1 million in Q2, including a $4.1 million write-off.
• Freezers and Thaw Systems platform revenue decreased by 7% year-over-year and 4% sequentially in Q2.
• The company's cash, cash equivalents, and marketable securities decreased to $36.9 million as of June 30, 2024, from $50.2 million at the end of 2023.

Risks

• The company's financial results are subject to fluctuations and may be impacted by market conditions.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's non-GAAP financial measures may not be comparable to those of other companies.
• The company's reliance on the cell and gene therapy market makes it vulnerable to changes in that industry.

Future Outlook

BioLife Solutions expects full-year positive adjusted EBITDA and adjusted EBITDA growth in 2024 and has raised its full-year revenue guidance to $99.0 million to $101.0 million.

Management Comments

• Roderick de Greef, Chairman and CEO, stated that the business has stabilized and momentum continues with the third consecutive quarter of sequential revenue growth.
• de Greef also noted that the company is beginning to benefit from the strength of its high margin, recurring and consumable product offerings.
• de Greef highlighted the company's strategic alignment with favorable secular trends in the cell and gene therapy market.

Industry Context

BioLife Solutions operates in the cell and gene therapy market, which is experiencing significant growth and increased regulatory approvals. The company's focus on biopreservation solutions positions it well to capitalize on these trends. The divestiture of the freezer division allows the company to focus on its core cell processing platform.

Comparison to Industry Standards

• BioLife Solutions' gross margin of 51% is a positive indicator, suggesting efficient cost management compared to some peers in the bioproduction space.
• The company's adjusted EBITDA of 17% of revenue shows a strong profitability trend, which is favorable compared to companies in similar growth phases.
• The company's focus on cell processing and biopreservation aligns with the industry's increasing demand for these services, particularly in the cell and gene therapy sector.
• Competitors like Cryoport and Thermo Fisher Scientific also offer biopreservation solutions, but BioLife's specific focus on cell and gene therapy gives it a competitive edge in that niche.
• The company's claim of supporting more than 70% of U.S. commercial CGT trials indicates a strong market position compared to other suppliers.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and improved profitability metrics.
• Employees may be encouraged by the company's positive momentum and strategic focus.
• Customers in the cell and gene therapy market will benefit from the company's continued innovation and product development.
• Suppliers may see increased demand for their products as the company expands its operations.

Next Steps

• Management will discuss the financial results and provide a business update during a conference call and webcast.
• The company expects 11 additional product approvals, geographic expansions, or new indications for its biopreservation media in the next 12 months.

Key Dates

Keywords

BioLife Solutions, Cell Processing, Biopreservation, Cell and Gene Therapy, EBITDA, Revenue Guidance, Gross Margin, Financial Results, Discontinued Operations, Stock Compensation